No Detail Found!

Combined Intravitreal Triamcenolone Acetonide and Bevacizumab for Refractory Diabetic Macular Edema.

Author(s)
Muhammad Aamir Arain Department of Vitreoretinal Surgery, Armed Forces Institute of Ophthalmology (AFIO), Rawalpindi, Pakistan
Waqar Muzaffar Department of Vitreoretinal Surgery, Armed Forces Institute of Ophthalmology (AFIO), Rawalpindi, Pakistan
Omer Farooq Department of Vitreoretinal Surgery, Armed Forces Institute of Ophthalmology (AFIO), Rawalpindi, Pakistan
Muhammad Naeem Azhar Department of Vitreoretinal Surgery, Armed Forces Institute of Ophthalmology (AFIO), Rawalpindi, Pakistan
Abstract
Objective: To evaluate the effectiveness of combined Intravitreal triamcinolone acetonide (IVTA) and Intravitreal Bevacizumab (IVB) for treatment of refractory diabetic macular edema. Study Design: Quasi-experimental study. Place and Duration of Study: Armed Forces Institute of Ophthalmology (AFIO), Rawalpindi, from January to December 2017. Methodology: Pseudophakic diabetic patients with macular edema refractory to prior treatment were included. Patients having best corrected visual acuity (BCVA) better than 20/40 (6/12) or worse than 20/200(6/60) or the central subfield thickness (CSFT) less than 300 um on spectral domain optical coherence tomography (OCT) were excluded. Effectiveness of treatment was compared in terms of change in BCVA and CSFT on OCT. Intravitreal injection of 2 mg IVTA and 1.25 mg of IVB was given. IVB was repeated on monthly basis in next two months. Follow-up was done after one week of first injection and then monthly for next three months. Results: Fifty eyes of 42 patients were studied. Mean age of the patients was 62.4 years +7.13. Male to female ratio was 2:1. Mean pre op LogMAR visual acuity was 0.708 +0.12 and CSFT was 439.10 +54.64 um. Mean postoperative LogMAR visual acuity was 0.586 +0.13 um and mean post op CSFT was 382.80 +56.12. There is statistically significant difference in improvement of LogMAR BCVA and decrease in CSFT after treatment. (p<0.001, paired t-test). Conclusion: Eyes with refractory macular edema showed improvement of visual acuity and reduction of CSFT at three months when treated with combined IVTA and IVB.
Publication Details
Page(s) 603-606
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 28, Issue: 8, Year: 2018

Request the full text from PASTIC

References
Nurözler TabakciB,ÜnlüN., 2017.Corticosteroid treatment in diabetic macular edema,Turk J Ophthalmol 47 156 -60
KleinR,KleinBE,MossSE,CruickshanksKJ, 1995.The Wisconsin epidemiologic study of diabetic retinopathy. XV. The long-term incidence of macular edema,Ophthalmology 102 7 -16
KleinR,KnudtsonMD,LeeKE,GangnonR,KleinBE, 2009.The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes,Ophthalmology 116 497 -503
DistefanoLN,Garcia-ArumiJ,Martinez-CastilloV,BoixaderaA, 2017.Combination of anti-VEGF and laser photocoagulation for diabetic macular edema: A review,J Ophthalmol 2407037 -
ScottIU,EdwardsAR,BeckRW, 2007.Diabetic retinopathy clinical research network. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema,Ophthalmology 114 1860 -7
2010.Diabetic retinopathy clinical research network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema,Ophthalmology 117 1064 -77
2012.Diabetic retinopathy clinical research network. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results,Ophthalmology 119 2312 -18
DoDV,NguyenQD,KhwajaAA, 2013.Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment,JAMA Ophthalmol 131 139 -45
ElmanMJ,AyalaA,BresslerNM, 2015.Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results,Ophthalmology 122 375 -81
2011.Diabetic Retinopathy Clinical Research Network. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema,Ophthalmology 118 609 -14
CiullaTA,HussainRM,CiullaLM, 2016.Ranibizumab for diabetic macular edema refractory to multiple prior treatments,Retina 36 1292 -7
QiHP,BiS,WeiSQ,CuiH,ZhaoJB, 2012.Intravitreal versus subtenon triamcinolone acetonide injection for diabeticmacular edema: a systematic review and meta-analysis,Curr Eye Res 37 1136 -47
Riazi-EsfahaniM,Riazi-EsfahaniH,AhmadrajiA, 2017.Intravitreal bevacizumab alone or combined with 1 mg triamcinolone in diabetic macular edema: a randomized clinical trial,Int Ophthalmol 27 1045 -6
IslamF,AshrafM,Zafar S, 2016.Retinal thickness and vsual acuity in diabetic macular edema: An optical coherence tomographybased study,J Coll Physicians Surg Pak 26 598 -601
SynekS, .BIntravitreal bevacizumab with or without triamcinolone for refractory diabeticmacular oedema,Coll Antropol 2010 Apr; 34 (Suppl 2 99 -103
AkinciogluD,KüçükevciliogluM,DurukanAH, 2017.Outcomes of intravitreal dexamethasone implant in the treatment of recalcitrant diabetic macular edema,Turk J Ophthalmol 47 274 -8
FurinoC,BosciaF,NiroA, 2017.Combined phacoemulsification and intravitreal dexamethasone implant (Ozurdex®) in diabetic patients with coexisting cataract and diabetic macular edema,J Ophthalmol 4896036 -
CalvoP,FerrerasA,Al AdelF,DangboonW,BrentMH, 2017.Effect of an intravitreal dexamethasone implant on diabetic macular edema after cataract surgery,Retina 10 -
FAMEStudy, 2011.Group: Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema,Ophthalmology 118 626 -35
2012.Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema,Ophthalmology 119 2125 -32
VerittiD,SaraoV,DiplottiL, .Fluocinolone acetonide for the treatment of diabetic macular edema,Expert Opin 18 1507 -16
QureshiNA,AliM,SyedAN, 2010.Mono therapy versus double therapy versus triple therapy in the treatment of diabetic macular edema Al-,Shifa J Ophthalmol 6 74 -80
MehmoodK,MalikBA,KhanMT, 2010.Visual effects of intravitreal triamcinolone acetonide injection in patients with refractory diabetic macular edema,Pak J Ophthalmol 26 193 -6
0

Citations

0

Downloads

102

Views